Search

Author/Creator Linde, R.

1. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease. Issue 3 (7th May 2015)

Authors:
Kriván, G.; Königs, Ch.; Bernatowska, E.; Salama, A.; Wartenberg‐Demand, A.; Sonnenburg, C.; Linde, R.
Journal:
Vox sanguinis
Issue:
Volume 109:Issue 3(2015)
Page Start:
248
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. The German national registry for primary immunodeficiencies (PID). (4th July 2013)

Authors:
Gathmann, B.; Goldacker, S.; Klima, M.; Belohradsky, B. H.; Notheis, G.; Ehl, S.; Ritterbusch, H.; Baumann, U.; Meyer‐Bahlburg, A.; Witte, T.; Schmidt, R.; Borte, M.; Borte, S.; Linde, R.; Schubert, R.; Bienemann, K.; Laws, H.‐J.; Dueckers, G.; Roesler, J.; Rothoeft, T.
Journal:
Clinical and experimental immunology
Issue:
Volume 173:Number 2(2013:Aug.)
Page Start:
372
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗